Vaxcyte, Inc. Stock

Equities

PCVX

US92243G1085

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 14:11:23 2024-07-18 EDT 5-day change 1st Jan Change
80.15 USD -1.50% Intraday chart for Vaxcyte, Inc. -2.41% +27.36%
Sales 2024 * - Sales 2025 * - Capitalization 8.85B 12.12B
Net income 2024 * -452M -619M Net income 2025 * -507M -694M EV / Sales 2024 * -
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * -
P/E ratio 2024 *
-20.3 x
P/E ratio 2025 *
-18.7 x
Employees 254
Yield 2024 *
-
Yield 2025 *
-
Free-Float 97.62%
More Fundamentals * Estimated data
Dynamic Chart
1 day-1.49%
1 week-2.41%
Current month+5.93%
1 month+10.71%
3 months+31.94%
6 months+31.47%
Current year+27.36%
More quotes
1 week
78.59
Extreme 78.59
85.61
1 month
71.17
Extreme 71.17
85.61
Current year
53.83
Extreme 53.83
85.61
1 year
44.20
Extreme 44.2
85.61
3 years
16.78
Extreme 16.78
85.61
5 years
15.51
Extreme 15.51
85.61
10 years
15.51
Extreme 15.51
85.61
More quotes
Managers TitleAgeSince
Founder 60 13-05-26
Founder 56 13-05-26
Director of Finance/CFO 55 20-04-30
Members of the board TitleAgeSince
Founder 56 13-05-26
Director/Board Member 57 21-09-15
Director/Board Member 56 18-04-30
More insiders
Date Price Change Volume
24-07-18 79.98 -1.70% 521 689
24-07-17 81.37 -2.25% 1,083,791
24-07-16 83.24 -1.10% 1,173,291
24-07-15 84.17 +2.16% 1,084,710
24-07-12 82.39 +0.52% 954,473

Delayed Quote Nasdaq, July 18, 2024 at 01:56 pm

More quotes
Vaxcyte Inc. is a clinical-stage vaccine company. It is engaged in developing a spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its lead candidate, VAX-24, is a Phase III-ready 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31, the Company’s next generation 31-valent PCV is developed for the prevention of IPD in adults. Its pipeline also includes VAX-A1, VAX-PG, and VAX-GI. VAX-A1, a novel conjugate vaccine candidate designed to prevent disease caused by Group A Streptococcus (Group A Strep). VAX-PG, a novel protein vaccine candidate targeting pathogen responsible for periodontitis, a chronic oral inflammatory disease. VAX-GI, a novel preclinical vaccine candidate being developed as a preventative treatment for dysentery and shigellosis. Its technology platform includes advanced chemistry and the XpressCF cell-free protein synthesis platform.
Related indices
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
81.37 USD
Average target price
103.1 USD
Spread / Average Target
+26.76%
Consensus